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The BIG1-98 trial
The BIG1-98 trial, involving over 8,000 postmenopausal
women with hormone receptor-positive early breast cancer,
was a four-arm trial of adjuvant endocrine therapy for early
breast cancer comparing 5 years of tamoxifen treatment
versus 5 years of letrozole treatment versus 2 years of
tamoxifen then switch to letrozole treatment versus 2 years of
letrozole then switch to tamoxifen treatment. The initial results
of the trial, which compared only the upfront tamoxifen and
letrozole arms, showed a small but highly statistically
significant disease-free survival (DFS) advantage in favour of
letrozole with a hazard ratio of 0.81 and an absolute 4-year
improvement in DFS of 2.7% [1].
These results were entirely compatible with the other major
upfront adjuvant aromatase inhibitor trial, the ‘Arimidex’,
Tamoxifen, Alone or in Combination (ATAC) trial. This was a
three-arm trial in which tamoxifen treatment for 5 years was
compared with anastrozole treatment for 5 years and com-
pared with the combination of the two treatments. This trial
likewise showed a DFS advantage in favour of anastrozole,
with a hazard ratio of 0.83 and a 4-year absolute disease-free
survival difference of 2.4% [2].
Neither the BIG1-98 trial or the ATAC trial showed any
significant overall survival benefit at first analysis.
In the BIG1-98 trial update, 4,922 patients were included in
the tamoxifen versus letrozole monotherapy comparison [3].
With a median follow-up of 76 months, letrozole treatment
continued to show a statistically significant DFS advantage
over tamoxifen therapy, with a hazard ratio of 0.88. In the
intent-to treat overall survival analysis there was a very strong
trend in favour of letrozole over tamoxifen that did not quite
reach statistical significance, with a hazard ratio of 0.7 (95%
confidence interval, 0.75 to 1.02). These results were
confounded, however, by 25% of patients initially randomised
to tamoxifen treatment electing to crossover to letrozole
treatment in 2005 when the initial results were announced.
Most of these patients crossed over in years 3 to 5 with a
median duration of letrozole treatment after crossover of
18 months. This led to a bias against letrozole because other
data (see below) have shown that a switch from tamoxifen to
an aromatase inhibitor after around 2 years is associated with
an improved DFS.
In a censored analysis to allow for this bias, the overall
survival ratio was significantly in favour of letrozole with a
hazard ratio of 0.81 (25% confidence interval, 0.69 to 0.94).
The true figure for overall survival difference probably lies
between these two analyses and would almost certainly show
a significant survival benefit for letrozole.
No suggestion of a similar survival advantage has been seen
in the ATAC trial, with the most recent hazard ratio for
tamoxifen treatment versus anastrozole treatment being 0.97.
The Femara versus Anastrozole Clinical Evaluation trial
directly compares letrozole with anastrozole in over 4,000
women with node-positive breast cancer, and will provide
data on whether letrozole does indeed achieve superior
clinical efficacy to anastrozole.
Prior to the BIG1-98 update, several trials (including IES,
ARNO, ABCSG and ITA) suggested that sequential adjuvant
aromatase inhibitors given after 2 to 3 years of tamoxifen
treatment had a significant DFS advantage over tamoxifen
alone, with hazard ratios ranging from 0.42 to 0.76. These
hazard ratios appeared superior to those achieved with the
upfront aromatase inhibitor approach compared with tamoxifen,
and led to speculation that sequential therapy starting with
tamoxifen and then switching after around 2 years might be
superior to starting with an aromatase inhibitor up front.
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The BIG1-98 trial update also addressed this issue. The trial
included for the first time randomised data on the sequential
therapy approach. Three blinded arms were compared:
letrozole treatment for 5 years versus 2 years of tamoxifen and
then switch to letrozole treatment versus 2 years of letrozole
and then switch to tamoxifen treatment. This evaluation had a
median follow-up of 71 months. Overall there was no
significant difference between any of the three treatments in
terms of 5-year DFS (87.9%, 87.6% and 86.2%, respectively).
Upfront letrozole treatment for 5 years, however, showed a
strong trend towards superiority over starting with tamoxifen
for 2 years and then switching to 3 years of letrozole
treatment. This was particularly seen in patients with node-
positive disease. No such trend was seen in the letrozole for
5 years versus letrozole then tamoxifen comparison.
In conclusion, the BIG1-98 trial update has for the first time
shown a very strong trend towards an overall survival
advantage in favour of upfront letrozole versus tamoxifen
treatment, which would probably have reached significance
without the confounding effect of crossover in the tamoxifen
arm. The update has also shown no advantage of starting with
tamoxifen for 2 years and then switching; indeed, the trend is
in the other direction. The evidence from the BIG 1-98 update
therefore argues strongly in favour of postmenopausal women
with early hormone receptor-positive breast cancer being
treated initially with letrozole 2.5 mg orally daily for 5 years in
the first instance. It is important to note, however, that
tamoxifen still remains a very effective alternative where toxicity
or cost issues cause problems with letrozole treatment.
The ZO-FAST trial
In the ZO-FAST trial 1,060 postmenopausal women with
hormone receptor-positive breast cancer being treated with
adjuvant letrozole 2.5 mg orally daily were randomised to
additional zoledronate 4 mg intravenously 6-monthly for
5 years versus zoledronate added only in the face of the bone
mineral density T score falling below –2 or the development
of clinical or asymptomatic fracture at 36 months (so-called
delayed treatment). The primary endpoint was the percentage
change in lumbar spine bone mineral density at 12 months,
but important secondary objectives included the incidence of
fractures at 3 years, the time to disease recurrence/relapse,
overall survival and safety.
The ZO-FAST trial achieved its primary endpoint demon-
strating a lumbar bone mineral density improvement of 4.39%
at 12 months in patients on immediate zoledronate compared
with a mean bone mineral density loss of –4.9% in those on
delayed zoledronate (P <0.0001). Similar changes were seen
for the hip. This overall difference in bone mineral density
emerged within 12 months of starting therapy and continued
to increase during year 2 and again during year 3.
Intriguingly, patients on immediate zoledronate treatment also
had a significantly decreased risk of DFS compared with
those on elective delayed therapy, with a hazard ratio of 0.59
(P = 0.03). This included a lower incidence of local recur-
rence (0.4% for immediate zoledronate versus 1.9% recurrence
for delayed zoledronate), suggesting the effect was not
simply mediated through inhibition of bone metastases
(where the difference was 1.7% vs. 3.2%, respectively). So
far 2.1% of patients have died following immediate
zoledronate treatment, versus 3.4% in the delayed arm. There
was no significant increased risk of adverse events with the
immediate treatment approach. No cases of renal impairment
related to the study drug were seen. Osteonecrosis of the
jaw was seen in one patient (0.2%) on immediate zoledronate
treatment versus none with the delayed approach.
Further evidence for an overall improvement in DFS with
immediate 6-monthly zoledronate comes from the ABCCSG-12
trial [4]. In this trial 1,803 premenopausal women were
randomised to tamoxifen and goserelin treatment versus
anastrozole and goserelin treatment. In a secondary randomi-
sation, all patients were also randomised to zoledronate
treatment versus no additional bisphosphonate therapy.
With 48 months median follow-up, the addition of 6-month
zoledronate therapy prevented bone mineral density loss,
which was seen in both endocrine therapy arms without
zoledronate.
In addition there was again an improvement in DFS for
patients randomised to receive immediate 6-monthly zoledro-
nate with a hazard ratio of 0.64 (P = 0.019) compared with
the delayed approach. As in the ZO-FAST trial, there was a
reduction in local regional relapse (10 patients vs. 20
patients) as well as in distant relapse including bone meta-
stases (23 patients vs. 16 patients). Sixteen patients have so
far died in those treated with zoledronate, versus 26 patients
in those without this treatment.
Zoledronate has several potential mechanisms of action to
explain this observation, including the induction of apoptosis,
the inhibition of tumour cell growth in vitro, inhibition of
adhesion and invasion, and possible anti-angiogenic effects.
Current National Institute of Clinical Excellence guidelines
and St Gallen recommendations suggest that bisphospho-
nates should not be used routinely as adjuvant therapy, but
should be guided by bone mineral density.
Although the ZO-FAST trial results are from early phases, the
fact that they are reinforced by very similar results from the
ABCCG-12 trial argues that current guidelines should be
changed and that zoledronate treatment by 6-monthly
intravenous infusion should be included as standard therapy
for women with hormone receptor-positive early breast
cancer. This inclusion of intravenous zoledronate is not just to
prevent bone mineral density loss but also on the basis of a
significant DFS advantage.Competing interests
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